Ashfaq Siddiqui, MD
Vascular Surgery · Mansfield, TXNPI 1417952623
Payments from drug & device makers
What this record shows
This record is dominated by education: $13,547 of the $14,654 with a category attached, or 92.4%. Angiodynamics, Inc. accounts for 93.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $5,089 and has fallen 98.2% since, to $92 in 2025.
Across 43 payments — averaging $340.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$14K
- Bard Peripheral Vascular, Inc.$465
- Tactile Systems Technology Inc$245
- Paratek Pharmaceuticals, Inc.$54
- Resmed Corp$31
- Boston Scientific$29
- plus $88 from 5 others
What the payments were for
- Food & beverage$1,1088%
- Education$13,54792%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 6 | $13,742 |
| Bard Peripheral Vascular, Inc. | 11 | $465 |
| Tactile Systems Technology Inc | 14 | $245 |
| Paratek Pharmaceuticals, Inc. | 3 | $54 |
| Resmed Corp | 2 | $31 |
| Boston Scientific | 2 | $29 |
| Bristol Myers Squibb | 1 | $22 |
| Artivion, Inc. | 1 | $19 |
| Acell, Inc. | 1 | $17 |
| Davol Inc. | 1 | $16 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVLT$9,600
- VenaCure 1470 Pro$3,947
How this compares
$14,654 in reported general payments places this provider in the 70th percentile of 347 vascular surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 18 | $292 |
| Alprazolam | 122 | $104 |
| Warfarin Sodium | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Mansfield
- Gregory PearlDallas$2.3M
- Mazin FotehAustin$1.6M
- Alan LumsdenHouston$742K
- Stephen HohmannDallas$499K
- Michael SiahDallas$392K
- Gustavo OderichHouston$319K
- Jean BismuthHouston$243K
- Carlos TimaranDallas$231K
- Dennis GableDallas$211K
- Thomas LohShenandoah$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.